2025.05.16
In the fast-evolving field of cell and gene therapy, preserving cell integrity during cryopreservation is non-negotiable. Kryogene™ Cell Freezing Media-CGT delivers exceptional post-thaw viability and functionality, validated through rigorous preclinical testing.
Proven Excellence in Cell Recovery
Across diverse cell types, Kryogene™ outperforms competitors with post-thaw viability rates exceeding 94%:
· hCD34+ hematopoietic stem cells maintained 94.9% viability after 3 months of storage, surpassing competitor results (94.3%).
· CAR-T cells frozen at high density (2.5E7/mL) retained >95% viability post-thaw, with CAR expression stability matching pre-freeze levels, even after 24-hour culture.
· Adipose-derived mesenchymal stem cells (MSCs) demonstrated >97% viability at Passage 5, with consistent surface marker expression (CD73+, CD90+, CD105+) through subsequent passages.
Validation in Immune Cell Functionality
For PBMCs and immune subtypes (CD3+/CD8+/CD14+), Kryogene™ ensured not only survival but functional resilience:
Mixed Lymphocyte Reaction (MLR) with dendritic cells (DCs) confirmed undiminished cytokine release (IL-2, IFN-γ), critical for therapeutic potency.
Robust Performance Across Applications
From iNK cells (90%+ viability with retained cytotoxicity) to tumor cell lines (CHO-K1, 293T: >93% recovery), Kryogene™ supports diverse workflows, including non-programmed freezing protocols with -80°C compatibility.
Why Choose Kryogene™?
· FDA Drug Master File listed, ensuring regulatory readiness.
· Optimized for high-density freezing and minimal DMSO stress.
· Validated in GMP-compliant settings for seamless scalability.
Elevate your cell therapy workflows with Kryogene™—where science meets reliability. Contact us at Info@milecell-bio.com to request validation data or samples.
